Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Elecoglipron on the Pharmacokinetics of Rosuvastatin and Atorvastatin in Healthy Participants
NCT07534592Phase 1Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Apr 2026
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of elecoglipron (2 arms), sponsored by AstraZeneca. Primary endpoints: Area under concentration-time curve from time 0 to infinity, Area under concentration-curve from time 0 to the last quantifiable concentration and 7 more. Started Apr 2026; status: active, not recruiting.
02
Drugs
elecoglipron
Beyond the preview
Go deeper on NCT07534592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07534592.